





# Ural pharmaceutical cluster is innovative project

Alexander P. Petrov, Ph.D. of economics

# Cluster platform is the base of state-private partnership

# Consolidation of state, business, science and manufacturing

- Political and financial state support
- Protection of common interests and promotion of the products
- Development of technological level
- Intensification of innovative activity
- Implementation of the innovative products in manufacturing
- Educational and social support of personnel



# Sverdlovskaya oblast – advantages of the base region

- Central region of Ural Federal district with total population
   12,5 millions people
  - Beneficial European-Asian geographical location
    - Developed industry and economic
      - The oldest Ural science school

- 194,3 thousands km<sup>2</sup>

- 4,4 millions people

26 billions Euro of gross regional

- product (2010)

1<sup>st</sup> place Volume of manufactured

products in metallurgy, pipe rolling and defense industry

5<sup>th</sup> place Turnover of retail trade

7<sup>th</sup> place Volume of Investments in

basic capital

11th place Volume of foreign

investments



## Structure of Ural pharmaceutical cluster

Manufacturers -12 pharmaceutical companies Science and personnel Customers -• UFU, USMA clinics of cluster Ural branch of RAS **Logistics & Sales -**International **Ural regional** pharmaceutical hub partners

#### **OUR STRATEGIC TARGET**

Forming in the region high-technology complex of interconnected manufacturers and infrastructure objects for developing, manufacturing and selling of the modern drugs, medical equipment and disposables of high quality.











#### **OUR MISSION**

Implementation and development of accessibility of the high medical technologies for extension of the people lifetime and improvement of life quality.

## Innovative infrastructure of Ural pharmaceutical cluster

Science and research park

Centers of the high medical technologies

Companies – residents of Innovative Fund "Skolkovo"

Business-Incubator and Center of personnel education

**R&D** with foreign partners

### **Ural Pharm Cluster - complex investment project**

- The 1<sup>st</sup> step of investment project till the year 2015 690 millions Euro
- The total investments
   till the year 2020 –
   about 1 billion Euro

Revenues from selling of cluster products:

- **2015** − 875 millions Euro
- 2020 2,5 billions Euro

By the year 2020 cluster will achieve the leading position in Russia by its production volume

#### **Our basic areas**

infusion solutions

genetically engineering

biotechnology and chemical substances

compound medical equipment dialysis concentrates

radioisotopes

antiviral, antineoplastic and other drugs















#### **Production of infusion solutions**

and pharmaceutical plastic

I.V. solutions

Production volume: 2010 – 12 millions bags 2011 – 25 millions bags

Total investments
– 14,5 millions Euro

Employees
- 420

Foreign partner – S.I.F.R.A., France





Plastic package

Production volume - 25 millions packages

Total investments
- 3,5 millions Euro

Employees
- 20





#### **Production of medical equipment**

#### and dialysis concentrates



Production of Kidney machines "Malakhit"



Production of water treatment systems



Production of dry and liquid dialysis concentrates

Production volume of:

Kidney machines500 per year;

- water treatment systems 100 per year.

Production volume of dialysis concentrates

– 5.500 tons per year

Total investments

- 6 millions Euro


**Employees** 


- 60

Foreign partner
Nipro Corp. Japan

– Nipro Corp., Japan

#### Production of radioisotopes





Production of Cs-131 isotopes for microinstrument with radiation frequency emission for primary and postoperative treatment of prostate malignant tumors by brachytherapy method

Production volume – 1.050 Ci per year Total investments – 1,25 millions Euro **Employees Exports of products** to USA - 100% Foreign partner IsoRay, USA

#### **New projects**

# Antiviral drug TRIAZAVIRIN

at the base of NEW molecule

**Total investments** 

- 52 millions Euro

Employees – 100

State grant

- 10 millions Euro





## Ural medical nuclear center

Science, production, clinic

Total investments - 12,5 millions Euro

Employees – 50

State grant – 3 millions Euro

#### **Ambulatory dialysis clinics**

Перспективное изображение

#### Медицинский центр на 18 диализных мест



Time of pilot project implementation in Sverdlovskaya oblast

2008-2012

Total investments – 36,5 millions Euro

Employees – 250

Secure state order for the service of clinics

#### **Ural Glass Plant**

The first company in Russia on production of ampoules, vials and cartridges of the 1<sup>st</sup> hydrolytic class for the needs of pharmaceutical industry.



Production volume per year: 2012 – 180 millions pieces 2015 – 1 billion pieces Total investments – 70 millions Euro **Employees** 

#### Cluster key factors of successful development



Skilled team of employees, including scientists and researchers:

- 3 academicians
  - 9 professors
    - 22 Ph.D.



Presence of independent private capital



Political support of all levels



State-private partnership

# Possible ways of cooperation in the frame of Ural pharmaceutical cluster

Joint R&D in creation of the modern, innovative drugs, medical equipment and disposables Development of products distribution at the Russian and international pharmaceutical markets

Projects of location of joint manufacturing at the facilities of cluster companies





28, Kirova str., 620028, Yekaterinburg, Russian Federation

Tel: + 7 343 376-14-64

Fax: + 7 343 246-91-56

e-mail: ap@uphc.ru